Literature DB >> 29276141

Direct In Vivo Reprogramming with Sendai Virus Vectors Improves Cardiac Function after Myocardial Infarction.

Kazutaka Miyamoto1, Mizuha Akiyama1, Fumiya Tamura1, Mari Isomi1, Hiroyuki Yamakawa1, Taketaro Sadahiro1, Naoto Muraoka1, Hidenori Kojima1, Sho Haginiwa1, Shota Kurotsu1, Hidenori Tani1, Li Wang2, Li Qian2, Makoto Inoue3, Yoshinori Ide4, Junko Kurokawa5, Tsunehisa Yamamoto1, Tomohisa Seki1, Ryo Aeba6, Hiroyuki Yamagishi7, Keiichi Fukuda1, Masaki Ieda8.   

Abstract

Direct cardiac reprogramming holds great promise for regenerative medicine. We previously generated directly reprogrammed induced cardiomyocyte-like cells (iCMs) by overexpression of Gata4, Mef2c, and Tbx5 (GMT) using retrovirus vectors. However, integrating vectors pose risks associated with insertional mutagenesis and disruption of gene expression and are inefficient. Here, we show that Sendai virus (SeV) vectors expressing cardiac reprogramming factors efficiently and rapidly reprogram both mouse and human fibroblasts into integration-free iCMs via robust transgene expression. SeV-GMT generated 100-fold more beating iCMs than retroviral-GMT and shortened the duration to induce beating cells from 30 to 10 days in mouse fibroblasts. In vivo lineage tracing revealed that the gene transfer of SeV-GMT was more efficient than retroviral-GMT in reprogramming resident cardiac fibroblasts into iCMs in mouse infarct hearts. Moreover, SeV-GMT improved cardiac function and reduced fibrosis after myocardial infarction. Thus, efficient, non-integrating SeV vectors may serve as a powerful system for cardiac regeneration.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Sendai virus; cardiomyocyte; fibroblast; integration; myocardial infarction; regeneration; reprogramming

Mesh:

Substances:

Year:  2017        PMID: 29276141     DOI: 10.1016/j.stem.2017.11.010

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  51 in total

Review 1.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

2.  In the heart of the in vivo reprogramming.

Authors:  Maurilio Sampaolesi; Enrico Pozzo; Robin Duelen
Journal:  Stem Cell Investig       Date:  2018-10-29

Review 3.  Therapeutic approaches for cardiac regeneration and repair.

Authors:  Hisayuki Hashimoto; Eric N Olson; Rhonda Bassel-Duby
Journal:  Nat Rev Cardiol       Date:  2018-10       Impact factor: 32.419

4.  Soluble expression, purification, and secondary structure determination of human MESP1 transcription factor.

Authors:  Krishna Kumar Haridhasapavalan; Sujal Harsh Ranjan; Srirupa Bhattacharyya; Rajkumar P Thummer
Journal:  Appl Microbiol Biotechnol       Date:  2021-03-02       Impact factor: 4.813

5.  Vascular Regeneration With New Sources of Endothelial Cells.

Authors:  Sangho Lee; Shin-Jeong Lee; Young-Sup Yoon
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 6.  Direct cellular reprogramming and inner ear regeneration.

Authors:  Patrick J Atkinson; Grace S Kim; Alan G Cheng
Journal:  Expert Opin Biol Ther       Date:  2019-01-02       Impact factor: 4.388

Review 7.  New Myocyte Formation in the Adult Heart: Endogenous Sources and Therapeutic Implications.

Authors:  Ronald J Vagnozzi; Jeffery D Molkentin; Steven R Houser
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

Review 8.  Direct cardiac reprogramming comes of age: Recent advance and remaining challenges.

Authors:  Yifang Xie; Jiandong Liu; Li Qian
Journal:  Semin Cell Dev Biol       Date:  2021-07-23       Impact factor: 7.727

9.  In Vitro Conversion of Murine Fibroblasts into Cardiomyocyte-Like Cells.

Authors:  Jun Xu; Li Wang; Jiandong Liu; Li Qian
Journal:  Methods Mol Biol       Date:  2021

Review 10.  Translational perspectives on cardiac reprogramming.

Authors:  Young-Jae Nam
Journal:  Semin Cell Dev Biol       Date:  2021-06-29       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.